Swiss National Bank
ALXN

Swiss National Bank’s Alexion Pharmaceuticals ALXN Stock Holding History

Swiss National Bank’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-900,881
Closed -$166M – 2636
2021
Q2 		$166M Buy
900,881
+58,950
+7% +$10.1M 0.1% 190
2021
Q1 		$129M Buy
841,931
+14,300
+2% +$2.21M 0.09% 236
2020
Q4 		$129M Sell
827,631
-31,900
-4% -$4.1M 0.09% 219
2020
Q3 		$98.4M Sell
859,531
-15,900
-2% -$1.72M 0.08% 251
2020
Q2 		$98.3M Buy
875,431
+16,600
+2% +$1.76M 0.08% 236
2020
Q1 		$77.1M Buy
858,831
+151,800
+21% +$14.9M 0.08% 237
2019
Q4 		$76.5M Sell
707,031
-33,500
-5% -$3.58M 0.08% 264
2019
Q3 		$72.5M Buy
740,531
+11,890
+2% +$1.34M 0.08% 270
2019
Q2 		$95.4M Sell
728,641
-16,000
-2% -$2.06M 0.1% 206
2019
Q1 		$101M Buy
744,641
+20,200
+3% +$2.51M 0.11% 194
2018
Q4 		$70.5M Buy
724,441
+14,100
+2% +$1.67M 0.09% 229
2018
Q3 		$98.7M Sell
710,341
-22,900
-3% -$2.87M 0.11% 194
2018
Q2 		$91M Buy
733,241
+16,400
+2% +$1.92M 0.1% 206
2018
Q1 		$79.9M Sell
716,841
-106,000
-13% -$12.7M 0.1% 221
2017
Q4 		$98.4M Sell
822,841
-4,300
-0.5% -$524K 0.11% 197
2017
Q3 		$116M Buy
827,141
+6,400
+0.8% +$870K 0.13% 171
2017
Q2 		$99.9M Buy
820,741
+26,100
+3% +$3.04M 0.12% 190
2017
Q1 		$96.3M Buy
794,641
+170,100
+27% +$21.9M 0.12% 189
2016
Q4 		$76.4M Buy
624,541
+2,800
+0.5% +$343K 0.12% 191
2016
Q3 		$76.2M Sell
621,741
-9,600
-2% -$1.24M 0.12% 187
2016
Q2 		$73.7M Buy
631,341
+46,000
+8% +$6.53M 0.12% 192
2016
Q1 		$78.1M Buy
585,341
+174,400
+42% +$25.6M 0.14% 156
2015
Q4 		$78.4M Buy
410,941
+10,900
+3% +$1.9M 0.19% 119
2015
Q3 		$62.6M Buy
400,041
+38,500
+11% +$7.02M 0.16% 145
2015
Q2 		$65.4M Buy
361,541
+59,524
+20% +$10.3M 0.17% 140
2015
Q1 		$52.3M Buy
302,017
+118,600
+65% +$21.5M 0.14% 171
2014
Q4 		$33.9M Sell
183,417
-6,200
-3% -$1.15M 0.13% 177
2014
Q3 		$31.4M Sell
189,617
-3,200
-2% -$526K 0.12% 192
2014
Q2 		$30.1M Buy
192,817
+2,800
+1% +$442K 0.11% 208
2014
Q1 		$28.9M Sell
190,017
-18,400
-9% -$2.93M 0.11% 203
2013
Q4 		$27.7M Sell
208,417
-2,900
-1% -$348K 0.11% 213
2013
Q3 		$24.5M Buy
211,317
+3,600
+2% +$395K 0.1% 226
2013
Q2 		$19.2M Buy
+207,717
New +$20M 0.08% 256

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Swiss National Bank's ALXN Position: Q3 2021 in Review

Swiss National Bank sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 900,881 shares — an estimated $166M sold.

Swiss National Bank first reported a position in ALXN in Q2 2013 and held it in 33 quarters. The position peaked at $166M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Swiss National Bank reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Swiss National Bank sold 900,881 Alexion Pharmaceuticals shares in Q3 2021, an estimated $166M.
  • Swiss National Bank first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 33 quarters.
  • Swiss National Bank's Alexion Pharmaceuticals position peaked at $166M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Swiss National Bank's 13F filing for Q3 2021, filed 8 Nov 2021.